PAP
RYTM icon

Persistent Asset Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Persistent Asset Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,446
Closed -$155K – 455
2025
Q4 		$155K Buy
+1,446
New +$153K 0.07% 242
2025
Q2 		– Sell
-11,501
Closed -$609K – 228
2025
Q1 		$609K Sell
11,501
-6,811
-37% -$378K 0.51% 55
2024
Q4 		$1.09M Buy
+18,312
New +$1.01M 0.9% 33

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Persistent Asset Partners's RYTM Position: Q1 2026 in Review

Persistent Asset Partners sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 1,446 shares — an estimated $155K sold.

Persistent Asset Partners first reported a position in RYTM in Q4 2024 and held it in 3 quarters. The position peaked at $1.09M in Q4 2024. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Persistent Asset Partners reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 1,446 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $155K.
  • Persistent Asset Partners first reported a position in Rhythm Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Persistent Asset Partners's Rhythm Pharmaceuticals position peaked at $1.09M in Q4 2024.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.